Skip to main content
Premium Trial:

Request an Annual Quote

Aiming for CLIA Certification, DermTech Begins Validation of Melanoma Test


DermTech said this week that it has begun commercial validation testing of its proprietary pigmented lesion assay, a non-invasive qPCR-based test for melanoma.

The San Diego-based company recently completed the build-out of a commercial laboratory space in nearby La Jolla, Calif. The company needs to complete analytical and clinical validation studies of its assay in order to receive regulatory certification under CLIA requirements.

DermTech recently raised $5.6 million in a Series B financing led by Jacobs Investment Company, and will use a portion of these funds to complete the validation of its assays.

The company's assays analyze the expression level of multiple gene targets using Life Technologies' OpenArray quantitative real-time PCR system (PCR Insider 8/22/2013). DermTech's initial assay will identify expression consistent with melanoma. The test uses an adhesive-patch method to collect cells from pigmented lesions including melanomas, allowing for non-invasive sample collection.

DermTech is conducting the validation studies in collaboration with Northwestern University and the University of Pittsburgh Medical Center.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.